Thrombocytosis: A paraneoplastic syndrome in patients with hepatocellular carcinoma

Shinn-Jang Hwang, Jiing-Chyuan Luo, Chung-Pin Li, Cheng-Wei Chu, Jaw-Ching Wu, Chiung-Ru Lai, Jen-Huei Chiang, Gar-Yang Chau, Wing-Yiu Lui, Chun-Chung Lee, Full-Young Chang, Shou-Dong Lee

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common malignancy in Taiwan. During its clinical course, patients may manifest a variety of paraneoplastic syndromes, including hypercholesterolemia, hypoglycemia, hypercalcemia, and erythrocytosis [7–9]. The prevalence of paraneoplastic syndromes was 11.4–12.1% for hypercholesterolemia, 2.8-5.3% for hypoglycemia, 1.8-4.1% for hypercalcemia, and 2.5-3.1% for erythrocytosis [2,4]. Thrombocytosis has been found in children with hepatoblastoma and other malignancies [7–9]. The prevalence and clinical significance of thrombocytosis in adult patients with HCC have not been previously reported.

Human thrombopoietin (TPO), also known as megakaryocyte growth factor, is known to play a key role in the development of megakaryocytes [10,11]. TPO is secreted principally by hepatocytes and bone marrow stromal cells [10,14]. In addition, the expression of TPO gene has been found in both rat and human hepatoma cell lines [15,16]. The relationships between serum TPO levels and platelet counts in HCC patients, especially those associated with thrombocytosis, are of clinical interest. Our aim was to evaluate the prevalence of thrombocytosis in Chinese patients with HCC in a retrospective study. The clinical, biochemical and image characteristics of HCC patients with thrombocytosis were evaluated. Moreover, in order to evaluate the role of serum TPO in the manifestations of thrombocytosis in HCC patients, serum TPO levels were measured in HCC patients (with and without thrombocytosis), in patients with cirrhosis, chronic hepatitis and healthy subjects in a cross-sectional study.

METHODS

We retrospectively reviewed clinical, biochemical and imaging data of 1 154 HCC patients. In addition, we measured platelet count and serum TPO in HCC patients with and without thrombocytosis, in patients with cirrhosis, chronic hepatitis and healthy subjects in a cross-sectional study.

RESULTS

Thirty-one (2.7%) of 1 154 HCC patients had thrombocytosis (platelet count >/=400 K/mm3). HCC patients with thrombocytosis were significantly younger, had a higher serum α-fetoprotein, higher rate of main portal vein thrombosis, larger tumor volume, shorter survival, and were less likely to receive therapy than HCC patients without thrombocytosis. Multivariate logistic regression analyses showed that tumor volumes >/=30% and serum α-fetoprotein >/=140 000 ng/mL could significantly predict thrombocytosis. HCC patients with thrombocytosis had a significantly higher mean serum TPO than those without, as well as patients with cirrhosis, chronic hepatitis and healthy subjects. Platelet count and serum TPO dropped significantly after tumor resection in HCC patients with thrombocytosis and re-elevated after tumor recurred.

Furthermore, the expression of TPO mRNA was found to be more in tumor tissues than in non-tumor tissues of liver in an HCC patient with thrombocytosis.

CONCLUSION

Thrombocytosis is a paraneoplastic syndrome of HCC patients due to the overproduction of TPO by HCC. It is frequently associated with a large tumor volume and high serum α-fetoprotein.

Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, Chang FY, Lee SD. Thrombocytosis: A paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10(17): 2472-2477 http://www.wjgnet.com/1007-9327/10/2472.asp

Abstract

AIM: Hepatocellular carcinoma (HCC) patients manifest a variety of paraneoplastic syndromes. Thrombocytosis was reported in children with hepatoblastoma. The aims of this study were to evaluate the prevalence and clinical significance of thrombocytosis in HCC patients and its relationships with serum thrombopoietin (TPO).

METHODS: We retrospectively reviewed clinical, biochemical and image data of 1 154 HCC patients. In addition, we measured platelet count and serum TPO in HCC patients with and without thrombocytosis, in patients with cirrhosis, chronic hepatitis and healthy subjects in a cross-sectional study.

RESULTS: Thirty-one (2.7%) of 1 154 HCC patients had thrombocytosis (platelet count >/=400 K/mm3). HCC patients with thrombocytosis were significantly younger, had a higher serum α-fetoprotein, higher rate of main portal vein thrombosis, larger tumor volume, shorter survival, and were less likely to receive therapy than HCC patients without thrombocytosis. Multivariate logistic regression analyses showed that tumor volumes >/=30% and serum α-fetoprotein >/=140 000 ng/mL could significantly predict thrombocytosis. HCC patients with thrombocytosis had a significantly higher mean serum TPO than those without, as well as patients with cirrhosis, chronic hepatitis and healthy subjects. Platelet count and serum TPO dropped significantly after tumor resection in HCC patients with thrombocytosis and re-elevated after tumor recurred.

LIVER CANCER
the 1,253 patients, data of 1,197 cases were analyzed after excluding the patients with incomplete examination and data for analysis. Finally, data of 1,154 patients were selected for analyses in this study after excluding 43 patients with an evidence of acute infections or gastrointestinal bleeding. Patients with polycythemia vera were also excluded.

We defined hypercholesterolemia in HCC patients as a serum cholesterol level greater than 250 mg/dL (two standard deviations above the mean value of age-and-sex-matched healthy controls); hypoglycemia as plasma glucose less than 60 mg/dL; hypercalcemia as corrected serum calcium level more than 11.0 mg/dL; and erythrocytosis as a hemoglobin level greater than 16.7 gm/dL, or hematocrit greater than 50% as in our previous reports[2,6]. Thrombocytosis was defined as having a platelet count greater than 400 K/mm³.

To compare the serum TPO level, 18 consecutive HCC patients with thrombocytosis and 72 age-sex-tumor volume matched HCC patients without thrombocytosis were consecutively collected in a cross-sectional study from January 1999 to December 2000. In addition, 42 age-sex-matched cirrhotic patients and 66 chronic hepatitis patients were randomly selected for comparison. The etiologies of chronic hepatitis and cirrhosis were either viral hepatitis B or hepatitis C, which were all confirmed by liver biopsies. None of the patients with chronic hepatitis or cirrhosis received interferon or other antiviral treatments before blood sampling. Alcoholic patients were not enrolled. Patients were also excluded if an acute infection or gastrointestinal bleeding was noted during enrollment. In addition, 62 healthy subjects who received their annual physical examinations at Taipei Veterans General Hospital, and whose age and sex were matched with the aforementioned 90 HCC patients, were randomly selected as healthy controls. Sera of the aforementioned subjects or patients were stored in aliquots at -70 °C until analyzed.

The underlying liver cirrhosis in HCC patients was diagnosed histologically or by characteristic image findings with the presence of ascites or esophageal varices. Patients with cirrhosis were given a score from 5-15 according to Child-Pugh’s classification[17]. Tumor volume was calculated from computerized tomographic films and was expressed as percentages of tumor volume in total liver volume. The grade of differentiation and the arrangement of tumor cells were assessed by a liver pathologist according to the classification of Edmondson and Steiner[18]. Tumor volume was calculated from computerized tomographic films and was expressed as percentages of tumor volume in total liver volume. The grade of differentiation and the arrangement of tumor cells were assessed by a liver pathologist according to the classification of Edmondson and Steiner[18]. The pathologist was not given any clinical information pertaining to the biopsy specimens.

All clinical data of HCC patients including age, sex, Child-Pugh’s scores, liver biochemistries (measured by a Hitachi Model 736 automatic analyzer, Tokyo, Japan), prothrombin time, and complete blood counts were recorded when an HCC was first diagnosed or at the time the thrombocytosis developed. Serum α-fetoprotein (AFP) was measured by a commercial kit (ELISA2-AFP, CIS bio-international, Cedex, France). Anti-HCV was measured by a second-generation enzyme immunoassay kit (Abbott Laboratories, Chicago, IL, USA). The serum markers of hepatitis B surface antigen (HBsAg) and antibody to hepatitis D virus (Abbott Laboratories) were recorded. Distant metastases to extrahepatic regional lymph nodes or other organs were evaluated by image studies. Methods of therapy for HCC, including surgical resection of tumors, transcatheter arterial chemoembolization (TACE), sono-guided percutaneous ethanol injection, or systemic chemotherapy and survival times were recorded in each patient. This study was approved by Taipei Veterans General Hospital, Taiwan.

Serum TPO levels were quantitatively measured by a solid phase enzyme immunoassay (QuantiGene, R&D systems, Abingdon, UK). For the expression of TPO mRNA, an equal amount of fresh frozen tumors and non-tumor parts of the liver samples from a patient with thrombocytosis who received lobectomy for HCC were homogenized with a pestle. Total RNA was purified by TRIZOL reagent (Invitrogen and Life Technologies, Rockville, MD, USA). Reverse transcription-polymerase chain reaction (RT-PCR) was carried out to amplify 1 µg RNA using the First-strain cDNA Synthesis Kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the instruction manual. PCRs were carried out with 35 cycles at 94 °C for 1 min, at 60 °C for 1 min and at 72 °C for 1 min. Primer sequences were sense: 5'-TGCGTTTCTGATGGT-3' and anti-sense: ' -AACCTTACCCCTCCCTGAGACA-3' [12], β-actin was used as an internal standard and diethyl pyrocarbonate-treated water was used as a negative control. The analysis of PCR products was performed by 20 µL agarose gel electrophoresis. For quantitation of TPO mRNA, the PCR product was purified by the QIAquick Gel Extraction Kit (QIAGEN GmbH, Hilden, Germany) and A_260 was measured to estimate the DNA contents. Serial dilutions of this standard were then included in the following real-time PCR along with samples to produce a standard curve. Quantitative PCR was performed in 20 µL reaction capillaries using 1× DNA master SYBR Green I mix (Roche Diagnostics, Indianapolis, IN, USA), bovine serum albumin, 4 mmol/L MgCl₂, 200 µmol/L dNTPs, 0.4 µL InViTaq-polymerase (InViTec, Berlin, Germany), 1 µL cDNA and 0.5 µmol/L of the TPO-specific sense and antisense primers. DNA amplification, data collection and analyses were performed with LightCycler (Roche Diagnostics)[19]. The program was optimized and performed finally as denaturation at 94 °C for 30 s followed by 40 cycles of amplification (at 94 °C for 0.1 s, 60 °C for 0.1 s, 72 °C for 20 s). The temperature ramp rate was 20 °C/s. At the end of each extension step, the fluorescence of each sample was measured to allow the quantification of the PCR product. After the PCR was completed, the melting curve of the product was measured by a temperature gradient from 60 °C to 96 °C at 0.2 °C/s with continuous fluorescence monitoring to produce a melting profile of the primers. For normalization, the amount of β-actin amplicon was divided by the amount of β-actin amplicon of the respective sample.

All data are expressed as mean±SD. Results were compared between groups using the Chi-square test, Fisher’s exact test, Student’s t-test, Mann-Whitney test or cross tabulation depending on the type of data analyzed. Survival adjusted for therapy was analyzed using the Kaplan-Meier method and was compared using the log rank method. Univariate and multivariate logistic regression using SPSS software (SPSS Inc., Chicago, IL, USA) were performed to evaluate the predictive values of the patients’ clinical, laboratory, and tumor features associated with thrombocytosis. For all tests, only the results with P values less than 0.05 (two-tail test) were considered to be statistically significant.

RESULTS

Among the 1,154 HCC patients (1,005 males, 149 females, mean age 62.0±12.0 years, with a range of 13 to 84 years), 735 (63.7%) patients were HBsAg positive, 180 (15.6%) were anti-HCV positive, 49 (4.3%) were positive for both HBsAg and anti-HCV and 19 (1.6%) were positive for HBsAg and antibody to hepatitis D virus. The mean serum AFP level was 43 983±163 097 ng/mL (median 268 ng/mL, range 3-1 892 500 ng/mL). Totally, 243 (21.1%) of 1,154 patients had paraneoplastic syndromes during the clinical course of HCC, in which 175 had a single paraneoplastic manifestation and 68 had multiple paraneoplastic manifestations. Thirty-one (2.7%) of 1,154 HCC patients had thrombocytosis (mean platelet count 484±68 K/mm³, range 403-688 K/mm³). The prevalence of hypercholesterolemia was 12.6%, hypoglycemia was 5.4%, hypercalcemia was 4.4%, and erythrocytosis was 3.2%. Eighteen of 31 HCC patients with thrombocytosis had other paraneoplastic manifestations.
(11 with hypercholesterolemia, 1 with hypoglycemia, 4 with hypercholesterolemia and hypoglycemia, 1 with hypercholesterolemia and hypercalcemia, and 1 with hypercholesterolemia, hypoglycemia and hypercalcemia). Nine-hundred and eleven HCC patients were free of paraneoplastic manifestations.

In comparison of the clinical, laboratory data and tumor features between HCC patients with thrombocytosis and those without, HCC patients with thrombocytosis were significantly younger in age, had a higher mean serum AFP level, higher rate of main portal vein (MPV) thrombosis, bilobar tumor involvement, larger tumor volume, were less likely to receive or be suitable for HCC therapy, and had a shorter survival time than those without thrombocytosis (Table 1). HCC patients with thrombocytosis tended to have more extra-hepatic metastases than those without thrombocytosis (32% vs 19%, P = 0.059). There were no significant differences in sex distribution, viral etiologies, mean Child-Pugh’s scores, and rates of cirrhosis between the two groups. Two hundred and fifty-eight (22%) of 1 154 HCC patients and 10 (32%) of 31 patients with thrombocytosis had their HCC tissues for histological analyses. Among the 10 HCC patients with thrombocytosis, tumor cell arrangement showed a trabecular pattern in 7 patients, and a mixed trabecular and acinar pattern in 3. Tumor cell differentiation revealed grade I in 3 patients, grade II in 4 patients, and grade III in 3 patients. The tumor cell arrangement and differentiation showed no significant differences between patients with and without thrombocytosis.

Age, sex, viral hepatitis markers, serum AFP, MPV thrombosis, metastases, bilobar tumor involvement, and tumor volumes were all selected as independent variables in logistic regression analyses, with the presence of thrombocytosis as the dependent variable. The continuous variables were transformed to categorical variables with the cut-off points determined by the Receiver Operating Characteristic Curve. In an univariate analysis, an age <60 years, serum AFP >140 000 ng/mL, tumor volume >30% of the total liver volume, bilobar tumor involvement, and MPV tumor thrombosis were significantly correlated with the presence of thrombocytosis (Table 2). In a stepwise multivariate analysis, a tumor volume >30% (odds ratio: 9.901, 95% confidence interval: 2.187-44.402, P = 0.003) and serum AFP >140 000 ng/mL (odds ratio: 2.660, 95% confidence interval: 1.090-6.487, P = 0.031) were significant predictive variables associated with the presence of thrombocytosis in HCC patients.

In the cross-sectional study, the mean platelet count was 440±43 K/mm³ (range 401 to 540 K/mm³) in 18 HCC patients with thrombocytosis, 174±100 K/mm³ (range 102 to 396 K/mm³) in 72 HCC patients without thrombocytosis, 72±29 K/mm³ (range 18 to 154 K/mm³) in 41 patients with cirrhosis, 178±48 K/mm³ (range 105 to 300 K/mm³) in 66 patients with chronic hepatitis, and 212±35 K/mm³ (range 125 to 347 K/mm³) in 62 healthy controls. The mean serum TPO level was significantly higher in HCC patients with thrombocytosis (404±196 pg/mL), when compared with HCC patients without thrombocytosis (181±85 pg/mL), cirrhotic patients (103±34 pg/mL), and healthy subjects (123±53 pg/mL) (Figure 1). Serum TPO levels were positively correlated with platelet counts among 90 HCC patients (r = 0.474, P<0.001). Among the 10 HCC patients with thrombocytosis, the

Table 1 Comparison of clinical and laboratory data, and tumor features between hepatocellular carcinoma (HCC) patients with and without thrombocytosis

| Age (yr)                | HCC patients with thrombocytosis (n = 31) | HCC patients without thrombocytosis (n = 1 123) | P value |
|-------------------------|------------------------------------------|------------------------------------------------|---------|
| Age (yr)                | 52±19                                    | 62±12                                          | <0.001  |
| Sex (male: female)      | 25;6                                     | 980:143                                       | 0.201   |
| HBV: HCV: HBV+HCV-related | 24:1:0                                    | 711:179:49                                    | 0.114   |
| Mean Child-Pugh’s scores| 7.2±2.1                                  | 6.8±2.2                                       | 0.336   |
| Mean platelet counts (k/mm³) | 484±87                                   | 154±80                                       | <0.001  |
| Median (range)          | 441 (403-688)                            | 133 (11-396)                                  |         |
| Mean α-fetoprotein (ng/mL) | 251 042±458 734                         | 57 879±212 788                               | <0.001  |
| Median (range)          | 4 859 (4-1 892 500)                     | 252 (3-1 621 700)                            |         |
| Cirrhosis (+: -)        | 23:8                                     | 913:210                                       | 0.445   |
| MPV tumor thrombosis (+: -) | 11:20                                   | 171:952                                       | 0.005   |
| Tumor metastases (+: -) | 10:21                                    | 196:927                                       | 0.059   |
| Tumor volumes %         | 63.5±21.2                                | 30.7±26.9                                     | <0.001  |
| Both lobes with tumor involvements (+: -) | 22:9                                   | 439:684                                       | <0.001  |
| Therapy for HCC (+: -)  | 10:21                                    | 583:540                                       | 0.048   |
| Mean survival (d)       | 144±208                                  | 373±521                                       | <0.001  |
| Median (range)          | 77 (4-852)                               | 147(2-3 666)                                  |         |

Data were expressed as means±SD. HBV: hepatitis B virus, HCV: hepatitis C virus, MPV: main portal vein.

Table 2 Significant predictive variables in association with thrombocytosis in hepatocellular carcinoma patients using univariate logistic analyses

| Variables                              | Odds ratio | 95% confidence interval | P value |
|----------------------------------------|------------|-------------------------|---------|
| Age <60 yr                              | 2.905      | 1.415-5.967             | 0.004   |
| α-fetoprotein >140 000 ng/mL¹           | 6.802      | 3.515-14.663            | <0.001  |
| Tumor volume >30%¹                      | 16.1       | 3.757-68.333            | <0.001  |
| Both lobes with tumor involvements       | 3.788      | 1.732-8.306             | <0.001  |
| Main portal vein tumor thrombosis       | 3.408      | 1.435-6.467             | 0.004   |

¹Significantly predictive variables in multivariate analyses.
mean platelet count dropped significantly from 420±48 K/mm$^3$ to 278±38 K/mm$^3$ (P<0.001) after a surgical tumor resection or TACE, while the mean platelet count for HCC patients with thrombocytosis, who did not receive any therapy, showed a progressive increase during follow up.

Figure 2 illustrates the relationship of platelet counts with the serum levels of cholesterol, AFP and TPO in a 36-year-old HCC male patient. The serum AFP level was 164,000 ng/mL and serum HBsAg was positive. Image studies revealed a large tumor mass over the right lobe of liver with an invasion to the left medial segment. Hypercholesterolemia (serum cholesterol level 602 mg/dL) and thrombocytosis (platelet count 403 K/mm$^3$) were noted at the diagnosis of HCC. He received a surgical removal of tumors followed by chemotherapy with 5-fluorouracil for 12 wk. Platelet counts, serum levels of cholesterol and AFP dropped significantly after a surgical removal of the tumors. However, all re-elevated when the tumor recurred 18 wk after surgical treatment. Serum TPO level was 360 pg/mL before surgery (platelet count 403 K/mm$^3$), and fell to 330 pg/mL one week after operation (platelet count 120 K/mm$^3$). Figure 3 shows the qualitative expression of TPO mRNAs using RT-PCR in tumor and matched non-tumor tissues of the resected liver samples. The expression of TPO mRNAs was more intensive in tumor than in the non-tumor liver tissues. The results from the quantitative real-time PCR also revealed that the concentration of TPO mRNAs in tumors was 1.92 times greater than in matched non-tumor liver tissues.

Figure 1 Distribution of serum thrombopoietin levels in hepatocellular carcinoma (HCC) patients with and without thrombocytosis, patients with cirrhosis, chronic hepatitis and healthy subjects. The mean serum thrombopoietin level in HCC patients with thrombocytosis was significantly higher than in HCC patients without thrombocytosis, patients with cirrhosis, chronic hepatitis and healthy subjects.

Figure 2 Clinical course of a hepatocellular carcinoma patient with thrombocytosis. The serum alpha-fetoprotein (AFP) level was 164,000 ng/mL before tumor resection. Hypercholesterolemia (serum cholesterol level: 602 mg/dL) and thrombocytosis (platelet count: 403 K/mm$^3$) were noted before operations. The platelet counts, serum levels of cholesterol and AFP fell significantly after a surgical removal of the tumors. However, all re-elevated when the tumor recurred 18 wk after surgical treatments.

Figure 3 Analyses of thrombopoietin from tumor tissues (T) and non-tumor liver tissues (L) in a hepatocellular carcinoma patient with thrombocytosis using reverse-transcription polymerase chain reaction. β-actin was used as an internal standard (B). N: negative control. Results from an agarose gel electrophoresis showed a more intense density of thrombopoietin band from tumor tissues when compared with non-tumor liver tissues.

**DISCUSSION**

Common paraneoplastic syndromes seen in HCC patients include hypercholesterolemia, hypoglycemia, hypercalcemia, and erythrocytosis$^{[1]}$. Thrombocytosis has been reported in children with hepatoblastoma$^{[7-9]}$. The prevalence of thrombocytosis in HCC patients has not been previously reported. Our results showed that 2.7% of HCC patients had thrombocytosis which was defined as a platelet count >400 K/mm$^3$. The prevalence of thrombocytosis might be underestimated because most HCC patients were associated with liver cirrhosis, and thrombocytopenia was frequently seen in these patients.

The clinical significance of thrombocytosis in HCC patients were similar to HCC patients with other paraneoplastic syndromes, including hypercholesterolemia, hypoglycemia, hypercalcemia, and erythrocytosis$^{[10-11]}$. Large tumor volume, high serum AFP, high rates of MPV tumor thrombosis, low rates of receiving therapy and poor prognosis have been identified in HCC patients with thrombocytosis. According to the multivariate logistic regression analyses, HCC patients with thrombocytosis were characterized by a large tumor volume and high serum AFP. HCC patients with thrombocytosis seemed to have a similar life expectancy as HCC patients with erythrocytosis or hypercholesterolemia, and had a better prognosis than patients with hypoglycemia and hypercalcemia which were usually pre-terminal events$^{[8]}$.

Before the cloning of TPO, the cause of thrombocytosis in children with hepatoblastoma and in other malignancies remains unclear. TPO, a glycoprotein hormone, is a potent stimulator of the growth and maturation of megakaryocytes and platelet production$^{[12,13]}$. The main sites of TPO production are the liver and, to a lesser degree, the kidneys, bone marrow and spleen. Messenger RNA transcripts of TPO have been found mainly in the liver and released into circulation$^{[14-16]}$. Most TPO is bound with and degraded by circulating platelets and megakaryocytes in the bone marrow, and the serum level is low. Circulating TPO levels are inversely correlated with the number of TPO receptors (c-Mpl-molecules) in regulating megakaryocytopoiesis and platelet production. When thrombocytopenia develops, binding receptors decrease and serum TPO levels increase. Elevated TPO levels stimulate megakaryocytopoiesis and result in increased platelet production$^{[17-23]}$. This reverse relationship of platelet counts and serum TPO levels has been found in patients.
with hematological diseases[26,27]. Patients with cirrhosis were frequently associated with low platelet counts. However, serum TPO levels in cirrhotic patients were found to be lower than chronic hepatitis patients or normal subjects due to inadequate TPO production by the diseased livers[28-32]. Serum TPO of cirrhotic patients increased after orthotopic liver transplantation, which was followed by an increase in platelet counts[14,15,35]. Our results revealed serum TPO levels were significantly lower in cirrhotic patients than in patients with chronic hepatitis or normal controls, and were consistent with previous reports.

Despite the fact that hepatoma cells have been found to express TPO in vitro and in animal models, the mechanisms by which thrombocytosis develops in HCC patients have not been studied. According to our results, HCC patients with thrombocytosis had a significantly higher mean serum TPO level than HCC patients without thrombocytosis. In addition, the platelet counts and serum TPO levels in HCC patients with thrombocytosis dropped after a surgical removal of the tumor or TACE, and re-elevated when a tumor recurred. Changes of platelet counts and serum TPO levels were parallel to the changes of serum AFP. Furthermore, by using the reverse transcription and real-time PCR methods, we demonstrated that the expression of TPO mRNA was more in tumor tissues than in matched non-tumor tissues in an HCC patient with thrombocytosis. Our results were consistent with the report that thrombocytosis in patients with hepatoblastoma was related to increased TPO production in tumors[33]. Thus, we speculate that thrombocytosis in HCC patients is due to the overproduction of TPO by HCC. HCC patients with thrombocytosis are associated with TPO production in tumors[9]. Thus, we speculate that thrombocytosis in HCC patients with a large tumor volume and high serum AFP level.

REFERENCES

1 Okuda K, Kondo Y. Primary carcinomas of the liver. In: Haubrich WS, Schaffner F, Berk JE, eds. Gastroenterology Volume 3. 5th ed. Philadelphia: W. B. Saunders 1995: 2467-2468.

2 Wu JC, Daughaday WH, Lee SD, Hsiao TSY, Chou CK, Lin HD, Tsai YT, Chiang BN. Radioimmunoperoxidase assay of serum IgF-I and IgF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988; 112: 589-594.

3 Hwang SJ, Lee SD, Chang CF, Wu JC, Tsay SH, Lui WY, Chang JH, Lo KJ. Hypercholesterolemia in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1992; 7: 491-496.

4 Yen TC, Hwang SJ, Wang CC, Lee SD, Yeh SH. Hypercalcemia and parathyroid hormone-related protein in hepatocellular carcinoma. Liner 1993; 13: 311-315.

5 Hwang SJ, Lee SD, Wu JC, Chang CF, Lu CL, Tsay SH, Lo KJ. Clinical evaluation of erythrocytosis in patients with hepatocellular carcinoma. Chin Med J 1994; 53: 262-269.

6 Luo JC, Hwang SJ, Li CP, Hsiao LT, Lai CR, Chiang JH, Lui WY, Chang FY, Lee SD. Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. Cancer 1999; 86: 799-804.

7 Nickerson HJ, Silverman TL, McDonald TP. Hepatoblastoma, thrombocytosis, and increased thrombopoietin. Cancer 1980; 45: 315-317.

8 Shafford EA, Ritchard JP. Extreme thrombocytosis as a diagnostic clue to hepatoblastoma. Arch Dis Child 1993; 69: 171-174.

9 Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16: 329-333.

10 de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, Oles KJ, Hultgren B Jr, Solberg LA, Goeddel DV, Eaton DL. Stimulation of megakaryocyteopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538.

11 Lok S, Kaushansky K, Holly RD, Kuiper JL, Loofman-DJ, Oort PJ, Grant FJ, Hepsel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O’harra PJ, Hagen FS, Roth JG, Foster DC. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 563-568.

12 Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 1997; 89: 101-107.

13 Nomura S, Ogami K, Kawamura K, Tsukamoto I, Kudo Y, Nakamura Y, Gitamura Y, Miyazaki H, Kato T. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997; 25: 565-572.

14 Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127: 285-288.

15 Shimada Y, Kato T, Ogami K, Horie K, Kuboko A, Kudo Y, Maeda E, Sohna Y, Akahori H, Kawamura K, Miyazaki H. Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995; 23: 1388-1396.

16 Hino M, Nishizawa Y, Tagawa S, Yamane T, Morii H, Tatsumi N. Constitutive expression of the thrombopoietin gene in a human hepatoma cell line. Biochem Biophys Res Commun 1995; 217: 475-481.

17 Pugh RN, Murray-Lyon M, Dawson JL, Pietroni MC, Williams R. Transsection of esophagus for bleeding esophageal varices. Br J Surg 1973; 60: 646-649.

18 Okuda K, Kondo Y. Primary carcinomas of the liver. In: Haubrich WS, Schaffner F, Berk JE, eds. Gastroenterology Volume 3. 5th ed. Philadelphia : W. B. Saunders 1995: 2462-2463.

19 Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LighCycler™ a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176-181.

20 McCarthy JM, Sprugel KH, Fox NE, Sahab DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-3675.

21 Nichol JM, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J. Megakaryocyte-growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95: 2973-2987.

22 Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88: 2578-2584.

23 Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567-573.

24 Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to increased platelet destruction. Blood 1996; 87: 4068-4071.

25 Eaton DL, de Sauvage FJ. Thrombopoietin: the primary regulator of megakaryocyteopoiesis and thrombopoiesis. Exp Hematol 1997; 25: 1-7.

26 Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, Matsumoto A, Miyazaki H, Urabe A, Kato A. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematology 1996;
27 Tomita N, Motomura S, Sakai R, Fujimaki K, Tanabe J, Fukawa H, Harano H, Kanamori H, Ogawa K, Mohri H, Marata A, Kodama F, Ishigatsu Y, Tahara T, Kato T. Strong inverse correlation between serum TPO level and platelet count in essential thrombocytopenia. Am J Hematol 2000; 63: 131-135

28 Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlisch J, Lipinski E, Langle F, Steininger R, Muhlbacher F, Gang A. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27: 127-131

29 Sezai S, Kamisaka K, Ikegami F, Usuki M, Urabe A, Tahara T, Kato T, Miyazaki H. Regulation of hepatic thrombopoietin production by portal hemodynamics in liver cirrhosis. Am J Gastroenterol 1998; 93: 80-82

30 Wolber EM, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology 1999; 29: 1739-1742

31 Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E, Romagnoli P, Testa E, Chiaronibello B, Polegato S, Mannone M, Testa R. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus related chronic hepatitis. J Hepatol 2002; 37: 572-577

32 Koruk M, Onuk MD, Akcay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002; 49: 1645-1648

33 Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 44: 754-758

34 Faeh M, Hauser SP, Nydegger UE. Transient thrombopoietin peak after liver transplantation for end stage liver disease. Br J Haematol 2001; 112: 493-498

35 Tsukahara A, Sato Y, Yamamoto S, Suzuki S, Nakatsuka H, Watanabe T, Kameyama H, Hatakeyama K. Thrombopoietin levels and peripheral platelet counts following living related donor liver transplantation. Hepatogastroenterology 2003; 50: 227-230

36 Suva LJ, Winslow GA, Weltenhall RE, Hammonds RG, Moseley JM, Difenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237: 893-896

37 Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58: 2485-2488

Edited by Zhu LH and Xu FM